Indian startup Miraqules MedSolutions, led by Sabir Hossain of Purba Bardhaman (West Bengal), won SLINGSHOT 2026 in Singapore for StopBleed, a haemostatic powder.
It topped the Health and Biomedical category and was named the overall Grand Winner, with a S$400,000 Startup SG grant prize; more than 5,000 startups entered.
SLINGSHOT is Enterprise Singapore's deep-tech pitching competition; the 2026 finals ran from 27 to 29 October at SWITCH, and the win was reported in India in early November.
StopBleed, developed from research at NIT Rourkela, uses nano-biopolymers to control severe bleeding within 60 seconds and is approved by CDSCO as a Class C medical device.
Platelets first form a temporary plug; clotting factors then build fibrin strands that strengthen it, with factor XIIIa cross-linking fibrin at the end. StopBleed's nano-biopolymers absorb plasma quickly and trap blood cells, concentrating them so this natural cascade runs faster.
Simple Analogy: A sponge that soaks up water and leaves the bricks behind to build the wall faster.
National regulator for drugs and medical devices, under the Directorate General of Health Services, Ministry of Health and Family Welfare; headed by the Drugs Controller General of India
Singapore government agency that organises SLINGSHOT at SWITCH
Institute where the StopBleed technology was developed before being spun out to Miraqules (founded 2018)
Classify devices by risk into Class A (low), B (low-moderate), C (moderate-high) and D (high); StopBleed's Class C approval is granted by CDSCO under these rules
General Awareness > Awards and honours; Science > Blood
An agent that stops bleeding by speeding up clot formation
Moderate-to-high-risk device category under India's Medical Devices Rules, 2017